Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-label, Rater-Blinded, Active-Controlled, International, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Flexibly Dosed Esketamine Nasal Spray Compared With Quetiapine Extended-Release in Adult and Elderly Participants With Treatment-Resistant Major Depressive Disorder Who Are Continuing a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor

Next Previous
X
Search
Trial Profile

A Randomized, Open-label, Rater-Blinded, Active-Controlled, International, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Flexibly Dosed Esketamine Nasal Spray Compared With Quetiapine Extended-Release in Adult and Elderly Participants With Treatment-Resistant Major Depressive Disorder Who Are Continuing a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 Feb 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Esketamine (Primary) ; Neurotransmitter uptake inhibitors; Quetiapine; Serotonin uptake inhibitors
  • Indications Major depressive disorder
  • Focus Registrational; Therapeutic Use
  • Acronyms ESCAPE-TRD
  • Sponsors Janssen-Cilag

    • Most Recent Events

    • 24 Oct 2024 According to a Johnson & Johnson media release, company will present data from this study in an oral presentation at Psych Congress on October 31 at 1:30-3:30 p.m. ET and November 1 at 1:30-3:30 p.m. ET in the Exhibit Hall.
    • 08 Oct 2023 According to a Janssen media release, The findings from this study presented at the 36th European College of Neuropsychopharmacology Congress (ECNP 2023) taking place from 7 October to 10 October in Barcelona, Spain.
    • 08 Oct 2023 According to a Janssen Pharmaceuticals media release,Professor Eduard Vieta is an Investigator for the ESCAPE-TRD study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top